Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven prostate cancer.~* The prostate cancer should be staged T3-4NxMx or TxN1-3Mx or TxNxM1 according to the TNM classification or the patient should have rising PSA after failed local therapy and be candidate for androgen deprivation therapy.~* Serum testosterone levels \>5 nmol/L.~* Karnofsky performance index \>40.~* Expected survival \> 18 months.~* Absence of another malignancy, other than local dermatological, for the previous 5 years.~* Signed informed consent before entry into the study.~Exclusion Criteria:~* Prior hormonal treatment for prostate cancer within 6 months prior to study start.~* Use of finasteride (Proscar®) or dutasteride (Avodart®/Avolve®) within 2 months prior to study start.~* Presence of another neoplastic lesion or brain metastases.~* Prior hypophysectomy or adrenalectomy.~* Known or suspicion of vertebral metastases with risk of spinal compression.~* Severe kidney or liver failure (creatinine \> 2 times the upper normal limit, ASAT and ALAT \>3 times the upper normal limit).~* Any concomitant disorder or resulting therapy that is likely to interfere with patient compliance or with the study in the opinion of the Investigator.~* Participation in another study with an experimental drug within 3 months before study start or within 5 drug half-lives of the investigational drug (whichever is the longer).~* Known hypersensitivity to any of the test materials or related compounds.~* Known active use of recreational drug or alcohol dependence in the opinion of the Investigator.~* Any current use or use within 6 months prior to treatment start of medications which are known to affect the metabolism and/or secretion of androgenic hormones: ketoconazole, aminoglutethimide, oestrogens, and progesterone.~* Use of systemic or inhaled corticosteroids (topical application permitted).~* Use of anticoagulants: heparin and coumarine derivatives (acetylsalicylic acid permitted).~* Inability to give Informed Consent or to comply fully with the protocol.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triptorelin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).